Korro to Participate in Upcoming June Investor and Scientific Conferences
Korro Bio (Nasdaq: KRRO) will participate in several significant investor and scientific conferences in June 2024.
CEO Ram Aiyar, Ph.D., and CFO Vineet Agarwal will present at the Jefferies Global Healthcare Conference on June 6 at 2:00 p.m. ET.
CMO Dr. Kemi Olugemo will discuss Korro's lead RNA editing oligonucleotide candidate, KRRO-110, for treating Alpha-1 Antitrypsin Deficiency at the 2024 Alpha-1 Foundation National Conference on June 8 at 11:20 a.m. ET.
Senior VP Venkat Krishnamurthy, Ph.D., will participate in the 5th Annual RNA Editing Summit on June 20, engaging in a roundtable discussion and giving a presentation on the OPERA platform and its clinical progress.
The Jefferies presentation will be webcast live, with a replay available for 30 days on Korro's website.
- Participation in high-profile investor and scientific conferences can enhance visibility and credibility.
- Presentation of lead candidate KRRO-110 shows progress in RNA editing technology.
- Discussions and presentations by top executives indicate strong leadership and expertise.
- Webcast of the Jefferies presentation offers accessibility to a broader audience, potentially attracting more investors.
- No new clinical or financial data updates were provided in the press release.
- Potential delays or issues with the OPERA platform progress were not addressed.
- The impact of these presentations on stock performance remains uncertain.
CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that members of management will participate in the following upcoming investor and scientific conferences:
Jefferies Global Healthcare Conference
Chief Executive Officer and President, Ram Aiyar, Ph.D., will present on Thursday, June 6, 2024, at 2:00 p.m. ET. Chief Financial Officer, Vineet Agarwal, will also be participating at the conference.
2024 Alpha-1 Foundation National Conference
Chief Medical Officer, Kemi Olugemo, M.D., FAAN, will discuss Korro’s lead RNA editing oligonucleotide candidate in a presentation titled, “KRRO-110, a RNA Editing Modality for the Treatment of Alpha-1 Antitrypsin Deficiency” on Saturday, June 8, 2024, at 11:20 a.m. ET.
5th Annual RNA Editing Summit
Senior Vice President & Head of Platform, RNA Editing, Venkat Krishnamurthy, Ph.D., will participate in a roundtable discussion titled “Discussing Strategies for Improved Longevity of Editing Therapeutics to Achieve More Durable Effects” on Thursday, June 20, 2024. at 11:00 a.m. ET.
Dr. Krishnamurthy will also deliver a presentation titled “Edit the Message: Rewrite the Future” on June 20 at 1:30 p.m. ET. This presentation will provide an update on Korro’s proprietary OPERA platform (Oligonucleotide Promoted Editing of RNA) and its progress towards the clinic.
A live webcast of the Jefferies presentation can be accessed on the “Events & Presentations” page in the Investor section of Korro’s website at www.korrobio.com. Following the presentation, a replay of the event will be available for 30 days.
About Korro
Korro is a biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly prevalent diseases using its proprietary RNA editing platform. Korro is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro is expanding the reach of genetic medicines by delivering additional precision and tunability, which has the potential for increased specificity and improved long-term tolerability. Using an oligonucleotide-based approach, Korro expects to bring its medicines to patients by leveraging its proprietary platform with precedented delivery modalities, manufacturing know-how, and established regulatory pathways of approved oligonucleotide drugs. Korro is based in Cambridge, Massachusetts. For more information, visit korrobio.com.
Korro Contact Information
Investors
IR@korrobio.com
Media
Glenn Silver
FINN Partners
Glenn.silver@finnpartners.com
FAQ
When will Korro Bio present at the Jefferies Global Healthcare Conference?
What will Korro Bio's CMO discuss at the 2024 Alpha-1 Foundation National Conference?
Who from Korro Bio will participate in the 5th Annual RNA Editing Summit?
How can I access the webcast of Korro Bio's presentation at the Jefferies Global Healthcare Conference?
What is Korro Bio's stock symbol?
